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Purpose. A case report evaluating flucytosine dosing in a critically ill patient receiving continuous renal replacement therapy.
Summary. This case report outlines an 81-year-old male who was receiving continuous venovenous hemofiltration (CVVH) for
acute renal failure and was being treated with flucytosine for the treatment of disseminated Cryptococcus neoformans infection.
Due to patient specific factors, flucytosine was empirically dose adjusted approximately 50% lower than intermittent hemodialysis
(iHD) recommendations and approximately 33% lower than CRRT recommendations. Peak and trough levels were obtained, which
were supratherapeutic, and pharmacokinetic parameters were calculated. The patient experienced thrombocytopenia, likely due to
elevated flucytosine levels, and flucytosine was ultimately discontinued. Conclusion. Despite conservative flucytosine dosing for a
patient receiving CVVH, peak and trough serum flucytosine levels were supratherapeutic (120 𝜇g/mL at 2 hours and 81 𝜇g/mL at
11.5 hours), which increased drug-related adverse effects. The results indicate that this conservative dosing regimen utilizing the
patient’s actual body weight was too aggressive. This case report provides insight into flucytosine dosing in CVVH, a topic that has
not been investigated previously. Further pharmacokinetic studies of flucytosine dosing in critically ill patients receiving CVVH
are needed in order to optimize pharmacokinetic and pharmacodynamic parameters while avoiding toxic flucytosine exposure.

1. Background
Amphotericin and flucytosine are the first-line agents for the
treatment of cryptococcal meningoencephalitis [1]. Dosing
of flucytosine is weight based and is typically 25 mg/kg/dose
every 6 hours for at least 4 weeks for cryptococcal meningoencephalitis in non-HIV infected, nontransplant patients.
A shorter, two-week course of induction therapy may be
considered for patients who have low risk of therapeutic
failure, who were previously healthy with no underlying,
uncontrolled disease states, and who have had an excellent
clinical response to the initial two-week combination. Six
weeks of induction therapy may be required in patients with
neurological complications. Consolidation and then maintenance therapy are recommended following the induction
stage, for a total of 6–12 months of treatment. The Infectious
Diseases Society of America (IDSA) Guidelines elaborate on

numerous caveats in the event that patients are unable to
tolerate the first-line antifungal combination for cryptococcal
infections.
Regarding flucytosine dosing in patients with severe renal
impairment requiring renal replacement therapy, limited
evidence exists regarding the appropriate dosing. In fact,
a boxed warning, a caution issued by the U.S. Food and
Drug Administration (FDA) regarding serious adverse drug
reactions, suggests extreme caution be utilized if flucytosine
is warranted in patients with renal dysfunction [2].
Flucytosine (5-fluorocytosine; 5-FC) is one of the oldest
antifungal agents on the market. Initially synthesized in 1957
as a potential antitumor agent, flucytosine was later approved
to treat human candidiasis and cryptococcosis [3]. Flucytosine penetrates susceptible fungal cells where it is converted
to fluorouracil (5-FU) via the enzyme cytosine deaminase [2–
4]. Fluorouracil is converted into several active metabolites
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Table 1: Flucytosine dosing recommendations in renal impairmenta [3, 5, 8–10].

Flucytosine dosing of 100 mg/kg/day (normal renal function)
CrCL (mL/min)
Dose
>50
10–50
<10
Hemodialysis
CRRT

25 mg/kg every 6 hours
25 mg/kg every 12–24 hours
25 mg/kg every 24–48 hours
Single, supplemental doses of 20–50 mg/kg after
dialysis sessions
No specific recommendations

Flucytosine dosing of 150 mg/kg/day (normal renal function)
CrCL (mL/min)
Dose
>40, >50
20–40, 10–50
<20, <10

37.5 mg/kg every 6 hours
37.5 mg/kg every 12–24 hours
37.5 mg/kg every 24–48 hours

Hemodialysis

Single, supplemental doses after dialysis sessions

CRRT

CVVHD/CVVH: 37.5 mg/kg every 12–24 hours

a

CrCL: creatinine clearance, CRRT: continuous renal replacement therapy, and CVVHD/CVVH: continuous venovenous hemodialysis/continuous
venovenous hemofiltration.

that falsely incorporate into the fungal RNA or interfere with
fungal DNA, ultimately inhibiting fungal protein synthesis
[2]. Flucytosine is readily absorbed with a bioavailability of
75–90% following oral administration [5, 6]. In the United
States, flucytosine is only available in oral capsule dosage
form (250 mg, 500 mg capsules) [2]. Due to the high water
solubility, flucytosine is not well distributed into adipose
tissues, with a volume of distribution range of 0.6–0.9 L/kg
at steady state [6–9]. Due to the limited distribution, dosing
in obese patients should be based upon ideal body weight
[4]. Distribution sites of flucytosine include the cerebrospinal
fluid (CSF), aqueous humor, joints, and peritoneal fluid. In
fact, CSF concentrations can reach up to 60–90% of serum
flucytosine concentrations [5]. Flucytosine is minimally protein bound, approximately 2–4%, and it undergoes minimal
hepatic metabolism with more than 90% of the drug excreted
unchanged in the urine, resulting in the need for renal dosage
adjustments [4, 5]. The elimination half-life of flucytosine is
typically 2–5 hours in patients with normal renal function;
however, the half-life can increase up to 250 hours in patients
with end stage renal disease or patients who are anuric [9].
No specific renal dose adjustment is recommended per the
package insert directly, but the manufacturer recommends
dose reduction in patients with impaired renal function.
In patients receiving intermittent hemodialysis (iHD), it is
recommended to administer flucytosine after dialysis, as
flucytosine is dialyzable [8, 9]. Data for dosing flucytosine in
continuous renal replacement therapy are scarce. See Table 1
for flucytosine dosing recommendations, which are dependent upon flucytosine total daily dose of either 100 mg/kg or
150 mg/kg [8, 9]. Utilizing recommended dose adjustments is
pertinent, as flucytosine is associated with potentially severe
adverse effects. Hepatotoxicity and bone marrow suppression
(agranulocytosis, aplastic anemia, leukopenia, pancytopenia,
and thrombocytopenia) are life-threatening conditions that
can occur as a result of flucytosine therapy, which limits use
in certain patients. Additional adverse effects of flucytosine
include cardiac toxicity, central nervous system toxicity, and
renal abnormalities.
In vivo studies indicate time above minimum inhibitory
concentration (MIC) is the pharmacodynamic parameter
most correlated to outcome with flucytosine monotherapy
[3, 4]. Peak flucytosine efficacy has been reported at serum

concentrations four times the MIC [6, 7]. The standard
flucytosine dose of 100–150 mg/kg/day in non-HIV infected
patients targets serum concentrations of ten times the MIC
breakpoint of 4 𝜇g/mL. This suggests that much higher serum
flucytosine concentrations are being obtained than required
for optimal efficacy.
Current data suggest obtaining a peak flucytosine level
once at steady state (after 3–5 doses), 2 hours after the oral
dose [6]. Based on available literature, the peak flucytosine
level should be 30–100 𝜇g/mL for the treatment of cryptococcal infections, and target flucytosine trough levels should
be 25–50 𝜇g/mL [3, 4]. Flucytosine concentrations above
100 𝜇g/mL should be avoided, as levels that elevated have
been associated with a greater incidence of thrombocytopenia and elevated liver enzymes [3, 4]. A general recommendation is to maintain flucytosine levels above 25 𝜇g/mL, but
under 100 𝜇g/mL, in order to optimize pharmacodynamic
parameters and avoid toxicity, although other sources suggest
steady-state serum flucytosine goal ranges of 50–100 𝜇g/mL
[4, 5].
The mode of renal replacement therapy plays a major
role in the amount and type of medications that are removed
during the dialysis session.
Key factors that determine the amount of drug removed
by CVVH are surface area of the filter, type of filter, blood flow
rate, replacement fluid rate, and location of replacement fluid
entry, prefilter or postfilter [10]. Drugs that are readily cleared
by CVVH are of low molecular weight, <500 Daltons, and low
protein binding, <80% protein bound, with a small volume
of distribution (Vd) ≤0.7 L/kg [11]. Flucytosine’s pharmacokinetic properties mostly match that of drugs readily cleared by
dialysis, as it is 129.1 Daltons in molecular weight and only 34% protein bound; however, the Vd has been reported as up to
0.9 L/kg in some studies (0.6–0.9 L/kg), which may limit the
amount of drug available to be removed by convection.

2. Case Report
An 81-year-old Caucasian male presented to the emergency
department with shortness of breath and hemoptysis. Over
the previous one to two months, the patient experienced
fatigue and increasing shortness of breath. Episodes of
hemoptysis were two to four times per day. His past medical
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history included ureteral and bladder cancer, recurrence
of papillary tumor and prostatic urethra status after right
nephroureterectomy and chemotherapy, deep vein thrombosis, hypertension, type 2 diabetes mellitus, and hypothyroidism. Regarding social history, the patient farmed fulltime in his retirement, and he had recently cleaned out his
chicken coop, which contained several months of built-up
feces and straw bedding.
Upon admission, initial laboratory values included
sodium 143 mEq/L, potassium 4.2 mEq/L, chloride 106 mEq/
L, blood urea nitrogen 58 mg/L, creatinine 4.29 mg/dL,
glucose 118 mg/dL, white blood cell count 9.7 × 103 /mm3 ,
hemoglobin 6.4 g/dL, and platelet count 169 × 103 /mm3 . Liver
function test values were alanine aminotransferase 6 U/L,
aspartate aminotransferase 13 U/L, and alkaline phosphatase
55 U/L. The patient was on warfarin for deep vein thrombosis,
and anticoagulation results indicated prothrombin time (PT)
108.2 seconds, international normalized ratio (INR) 9.6, and
activated partial thromboplastin time (aPTT) 49 seconds.
Numerous other laboratory tests were completed, including cytoplasmic anti-neutrophil cytoplasmic antibodies (cANCA), perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), glomerular basement membrane antibody
IgG, urine Histoplasma/Legionella/Streptococcus pneumoniae
antigens, QuantiFERON tuberculosis gold, and beta-glucan.
All of these tests were negative. Of note, beta-glucan test
does not reliably detect Cryptococcus, Zygomycetes, or Blastomyces dermatitidis. Abnormal laboratory values included
c-reactive protein 8.9 mg/dL, automated sedimentation rate
>120 mm/hr, N-terminal pro-brain natriuretic peptide (NTproBNP) 9,789 pg/mL, and troponin T 0.106 ng/mL.
The initial differential diagnosis and assessment included
inflammatory pneumonitis, infection, and immunologic
pathology. The patient was initiated on ceftriaxone and azithromycin, and a respiratory culture was obtained. Throughout
the initial hospital course, his oxygen saturation dropped on a
nonrebreather mask, and the patient was agreeable to elective
intubation with bronchoscopy. Antibiotics were broadened
to levofloxacin, piperacillin/tazobactam, and vancomycin,
and corticosteroids were added. Cystogram was completed
per urology which showed reflux with nonobstructive
hydronephrosis, and nephrology was consulted to rule out
other causes of the patient’s acute kidney injury, none of
which were definitive diagnoses. On hospital day 19, the
patient’s blood cultures were positive for yeast, which was
presumed to be Cryptococcus neoformans, and liposomal
amphotericin B 300 mg (3.1 mg/kg actual body weight) daily
was initiated. On hospital day 23, Cryptococcus neoformans
was identified in the blood via matrix assisted laser
desorption/ionization-time-of-flight (MALDI-TOF) mass
spectrometry and confirmed via a biochemical method (API
20C strip). A lumbar puncture was completed which also
grew Cryptococcus neoformans. Flucytosine was initiated on
day five of liposomal amphotericin B treatment (hospital day
23).
As the patient was receiving intermittent hemodialysis
at the time of flucytosine initiation, a dose of 2,500 mg
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Table 2: Hemodialysis sessions and corresponding flucytosine
administrations.
Hospital day

Event

14
18
20
22
23

Intermittent hemodialysis session
Intermittent hemodialysis session
Partial intermittent hemodialysis session
Intermittent hemodialysis session
Flucytosine 2,500 mg given
Intermittent hemodialysis session
Flucytosine 2,500 mg given

25

(25.8 mg/kg actual body weight) every Tuesday, Thursday,
and Saturday after dialysis sessions was chosen. See Table 2
for a schedule of the hemodialysis sessions the patient
received. On hospital day 27, the patient was initiated on
continuous renal replacement therapy due to hemodynamic
instability with the addition of multiple vasopressors (norepinephrine, phenylephrine, and vasopressin). The patient
remained intubated, sedated, and paralyzed for facilitation of
mechanical ventilation. Continuous venovenous hemofiltration (CVVH) was initiated (with citrate for anticoagulation)
as the primary mode of dialysis and was maintained on the
following settings: total replacement fluid rate, 2,500 mL/hr;
blood flow rate, 300 mL/min; preblood pump rate (PBP)
(citrate flow rate), 450 mL/hr; and ultrafiltration rate, 100–
400 mL/hr. Our institution utilizes the Gambro PrismaSATE
system with the PrismaSATE HF 1400 polyarylethersulfone
filter. Due to inability to ultrafiltrate with CRRT at all times,
the average fluid removal rate was 265 mL/day (11 mL/hr) over
3 days (hospital days 27–29).
As a result of the dialysis change to CVVH, the flucytosine
dose was increased to 2,500 mg (25.8 mg/kg actual body
weight) by mouth every 12 hours. Of note, this flucytosine
dose was significantly conservative, as it utilized a total daily
dose of 50 mg/kg/day, as compared to some literature that recommends up to 150 mg/kg/day divided. The choice for conservative flucytosine dosing was made based on the patient’s
baseline thrombocytopenia; the patient’s platelet count was
39 × 103 /mm3 the day CVVH was initiated. Over the 3 days of
CVVH, the patient had a mean urine output of approximately
0.21 mL/kg/day, classified as nonoliguric renal failure.
Flucytosine was discontinued on hospital day 29 due to
thrombocytopenia, and high dose fluconazole was added.
Liposomal amphotericin was replaced with conventional
amphotericin on hospital day 37. The patient had negative
blood cultures on hospital days 32 and 34.
The patient passed away on hospital day 47 from refractory hypoxemic respiratory failure, as life prolonging efforts
were withdrawn per family request.

3. Methods
As the patient was overweight and not quite obese (body mass
index, 29.7 kg/m2 ), flucytosine dosing was based upon the
patient’s actual body weight of 97 kg. The patient was initiated
on flucytosine 2,500 mg by mouth every 12 hours on hospital

4. Results
The patient’s flucytosine peak level resulted at 120 𝜇g/mL, and
the flucytosine trough level was 81 𝜇g/mL. Pharmacokinetic
calculations indicate an elimination rate constant (ke) of
0.04 hr−1 , with a half-life (t1/2) of 16.75 hours [12]. The volume
of distribution was 48.1–57.7 L (0.50–0.59 L/kg, range based
on bioavailability of 75–90%), the area under the curve (AUC)
was 2,980 𝜇g⋅hr/mL, and the total clearance was 1,924–
2,308 mL/hr (range based on bioavailability of 75–90%). The
minimum inhibitory concentration (MIC) for flucytosine
was reported as 2 𝜇g/mL; however, it was noted that no
Clinical Laboratory Standards Institute (CLSI) range exists
for flucytosine and Cryptococcus neoformans for susceptibility
interpretation. Results of the MIC are for research use only.
The patient’s serum flucytosine concentrations were well
above the concentration associated with peak flucytosine
efficacy, four times the MIC or 8 𝜇g/mL.
Figure 1 depicts the patient’s flucytosine concentrations.
As a result of the patient’s declining platelet count, flucytosine was discontinued on hospital day 29 (platelet count of
26 × 103 /mm3 ), 48 hours after CVVH was initiated. Figure 2
depicts the platelet count trend for the patient. The nadir
platelet count was 15 × 103 /mm3 , which occurred on hospital
day 31, 9 days after initiation of flucytosine. The patient was
receiving concomitant medications that could contribute to
thrombocytopenia during this time, including amphotericin,
cefepime, famotidine, metronidazole, and vancomycin.
Despite the elevated flucytosine levels, the patient did
not experience any hepatotoxicity. In fact, the patient’s liver
function tests throughout the course of his stay were lower
than or within normal range.

5. Discussion
The patient described above had a supratherapeutic flucytosine peak concentration of >100 𝜇g/mL and higher than
expected levels overall. Potential reasons for the higher flucytosine levels include potential accumulation of flucytosine
during the hemodialysis period, limited fluid removal from
CVVH, and limited time receiving CVVH before flucytosine
discontinuation (<72 hours). The initial flucytosine level of

140
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81
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Figure 1: Flucytosine concentration versus time.
250
Platelet count (×103 )

day 27. An initial flucytosine level was ordered without regard
to scheduled flucytosine doses (2 hours prior to the dose
while the patient was receiving CVVH), and it resulted at
90 𝜇g/mL (hospital day 28). Peak and trough flucytosine levels were obtained after the fifth dose of the CVVH flucytosine
regimen. Of note, prior to that, the patient had received three
doses of flucytosine 2,500 mg after intermittent hemodialysis
sessions. The peak level was obtained two hours after the
fifth dose of flucytosine, and the trough level was obtained 30
minutes prior to the next scheduled dose of flucytosine (11.5
hours after the previously administered dose). These peak
and trough levels were obtained on hospital day 29, but the
results were not reported until hospital day 38. Due to the
thrombocytopenic toxicity of flucytosine experienced by the
patient, flucytosine was discontinued on hospital day 29, prior
to the results of the peak and trough levels.

Case Reports in Critical Care

Concentration (𝜇g/mL)

4

Flucytosine initiated,
hospital day 23

200

Flucytosine discontinued,
hospital day 29

150
100
50
0

0

10

20
30
Hospital day

40

50

Figure 2: Platelet count trend.

90 𝜇g/mL, albeit drawn 2 hours prior to the flucytosine dose,
indicates that the patient was likely accumulating flucytosine
while receiving intermittent hemodialysis, as this level was
obtained after only 4 flucytosine doses (2 iHD doses and 2
CRRT doses). As the method of CVVH utilizes a convectiononly method of solute removal, this may have limited the
flucytosine removal and resulted in higher than expected
flucytosine levels. Flucytosine has a small molecular weight
(129.1 Daltons), which could explain the lower flucytosine
clearance seen with convection, as low molecular weight
solute is more efficiently removed by diffusion modalities
such as continuous venovenous hemodialysis (CVVHD) or
iHD.
Another potential reason for the flucytosine toxicity is
the use of the patient’s actual body weight for flucytosine
dosing. Although the patient was not technically obese, the
patient was overweight, and potentially utilizing adjusted
(80 kg) or ideal body weight (75 kg) would have resulted in
therapeutic flucytosine levels. Dodds and colleagues suggest
utilizing ideal body weight in obese patients; however, limited
literature exists regarding the weight utilized for flucytosine
dosing in patients who are overweight, and consensus does
not exist.
The patient was receiving multiple vasopressors as well
as trophic tube feeds during the time of flucytosine administration and CVVH. Food decreases the rate of flucytosine
absorption, but it does not impact the extent of absorption
[5]. Therefore, we believe the trophic tube feeds had minimal
impact on the patient’s flucytosine concentrations.
In comparing the patient-specific flucytosine pharmacokinetics to what is documented in the literature, the patient

Case Reports in Critical Care
had a lower volume of distribution (0.50–0.59 L/kg) than
the general population (0.6–0.9 L/kg). Our observed reduced
volume of distribution offers no explanation as to the reduced
flucytosine clearance.
As this is the first published case of its kind regarding
flucytosine dosing in CVVH, we believe our findings make
a significant contribution to the critical care literature.

6. Conclusion
Flucytosine is recommended as a component of the firstline antifungal combination for the treatment of cryptococcal
infections. Despite its use for many years, optimizing flucytosine dosing in critically ill patients on renal replacement
therapy remains difficult, as clinical data are lacking in this
patient population. In our patient summarized above, the
total clearance of flucytosine by CVVH was less than expected
and resulted in significant hematologic toxicities, warranting
drug discontinuation. Our patient experienced significant
toxicities related to the supratherapeutic flucytosine levels,
even though the empiric dosing regimen was conservative,
approximately 1/2 the recommended iHD dose and 1/3 the
recommended CRRT dose [3, 5, 8–10]. As the patient was
overweight, yet not obese, potentially utilizing a lower dosing
regimen with the patient’s adjusted or ideal body weight
would have resulted in therapeutic serum levels and reduced
the risk of toxicity. As flucytosine is a mainstay of treatment
for patients with severe cryptococcal disease, it is paramount
that dosing recommendations more accurately reflect the
real world experience with CRRT dosing. This case report
provides insight into flucytosine dosing in CVVH, a topic
that has not been investigated previously in the literature.
Additional pharmacokinetic studies are needed to further
explore the pharmacokinetics of flucytosine removal with
CVVH, as the dosing regimens currently recommended may
be supratherapeutic and result in unwanted toxicities.
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